Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 54,972 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Kidney Failures, Acute
Interventions: Intra-Renal Fenoldopam, Furosemide; Drug
Lead sponsor: Southeast Renal Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: HIV-DDI
Interventions: Riociguat (Adempas, BAY 63-2521), ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, Antiretroviral protease inhibitor; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Orlando, Florida • Boston, Massachusetts

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 12
States / cities: Berkeley, California • Torrance, California • Washington D.C., District of Columbia + 6 more

Conditions: Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Interventions: Carboplatin, Paclitaxel, Pembrolizumab, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Kidney Disease
Interventions: BAY3283142, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 24
States / cities: Huntsville, Alabama • Chula Vista, California • San Dimas, California + 20 more

Conditions: Heart Failure
Interventions: Eplerenone; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 2,743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 51
States / cities: Phoenix, Arizona • Loma Linda, California • Merced, California + 37 more

Conditions: Pulmonary Fibrosis, Interstitial Lung Disease, Respiratory Disease
Interventions: Nintedanib, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Atlanta, Georgia • Baltimore, Maryland • New York, New York + 3 more

Conditions: Locally Recurrent or Metastatic Breast Cancer
Interventions: Imetelstat sodium, Bevacizumab, Paclitaxel; Drug
Lead sponsor: Geron Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 50
States / cities: Huntsville, Alabama • Berkeley, California • Campbell, California + 44 more

Conditions: Liver Cancer
Interventions: T900607; Drug
Lead sponsor: University Hospitals Seidman Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: CRPC, Prostate Cancer
Interventions: BIND-014; Drug
Lead sponsor: BIND Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Fort Meyers, Florida + 5 more

Conditions: Tachyarrhythmias, Sudden Cardiac Death, Heart Failure
Interventions: SJ4 connector and RV high voltage SJ4 lead; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 1,701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypertension
Interventions: Aliskiren, Amlodipine, Hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Santa Fe, New Mexico

Conditions: Free Tissue Flaps, Head and Neck Neoplasms
Interventions: surveys, evaluative tests for leg function; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Delirium
Interventions: Guanfacine, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Agitation
Interventions: Haloperidol, Midazolam; Drug
Lead sponsor: Catholic Health East; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Darby, Pennsylvania

Conditions: Coronary Artery Disease, Coronary Restenosis, Coronary Thrombosis
Interventions: Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent); Device
Lead sponsor: Paul S Teirstein, MD; Other
Eligibility: 18 Years and older
Enrollment: 859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Colorectal Cancer, Pancreatic Cancer, Lung Cancer
Interventions: Vitamin C; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Diabetes Mellitus, Type 1 Diabetes
Interventions: Culturally and linguistically tailored onboarding and support program, Medtronic MiniMed 780G Insulin Pump System; Other · Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years to 20 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Class IV Angina
Interventions: Not listed
Lead sponsor: CryoLife, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Jacksonville, Florida • Nashville, Tennessee

Conditions: Obesity
Interventions: DMAC, CMAC; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Small Cell Lung Carcinoma
Interventions: figitumumab, Cisplatin (Or Carboplatin), Etoposide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 34
States / cities: Washington D.C., District of Columbia • Marrero, Louisiana • Metairie, Louisiana + 28 more

Conditions: Stroke, Balance; Distorted
Interventions: Body weight support system control group, Body weight support system with balance perturbations; Device
Lead sponsor: Gaylord Hospital, Inc; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Wallingford, Connecticut

Conditions: PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
Interventions: BYL719, AMG 479; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Alzheimer's Disease
Interventions: Bexarotene, Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 50 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Las Vegas, Nevada

Search by objective public record fields.

Intra-Renal Therapy of Diuretic Unresponsive Acute Kidney Injury

Interaction With HIV Antiretroviral Agents

A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

A Comparison Of Outcomes In Patients In New York Heart Association (NYHA) Class II Heart Failure When Treated With Eplerenone Or Placebo In Addition To Standard Heart Failure Medicines

The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

T900607 in Treating Patients With Unresectable Liver Cancer

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

SJ4 Post Approval Study in Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Defibrillator Patients

An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure

Leg Function and ADL After ALT Reconstruction for Head and Neck Cancer

The Effect of Guanfacine on Delirium in Critically Ill Patients

Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient

The SCRIPPS DES REAL WORLD Registry

High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies

Supporting Medtronic 780G Insulin Pump Adoption in Latino Patients: A Spanish - Language Training Initiative

CardioGenesis Transmyocardial Revascularization 1-Year Follow-Up Study

Comparison of Storz C-MAC and D-MAC Orotracheal Intubation Systems in Morbidly Obese Patients

A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer

Explorations of the Benefits of the ZeroG TRiP System to Improve Balance in Patients Following Stroke

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

Bexarotene Amyloid Treatment for Alzheimer's Disease